- Home
- SCYX vs FMST Comparison
SCYX vs FMST Comparison
Compare SCYX & FMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- FMST
- Stock Information
- Founded
- SCYX 1999
- FMST 2005
- Country
- SCYX United States
- FMST Canada
- Employees
- SCYX N/A
- FMST N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- FMST Other Metals and Minerals
- Sector
- SCYX Health Care
- FMST Basic Materials
- Exchange
- SCYX Nasdaq
- FMST Nasdaq
- Market Cap
- SCYX 34.9M
- FMST 38.2M
- IPO Year
- SCYX 2014
- FMST N/A
- Fundamental
- Price
- SCYX $0.83
- FMST $3.11
- Analyst Decision
- SCYX
- FMST
- Analyst Count
- SCYX 0
- FMST 0
- Target Price
- SCYX N/A
- FMST N/A
- AVG Volume (30 Days)
- SCYX 167.5K
- FMST 440.3K
- Earning Date
- SCYX 08-13-2025
- FMST 08-13-2025
- Dividend Yield
- SCYX N/A
- FMST N/A
- EPS Growth
- SCYX N/A
- FMST N/A
- EPS
- SCYX N/A
- FMST N/A
- Revenue
- SCYX $3,257,000.00
- FMST N/A
- Revenue This Year
- SCYX $422.61
- FMST N/A
- Revenue Next Year
- SCYX $240.56
- FMST N/A
- P/E Ratio
- SCYX N/A
- FMST N/A
- Revenue Growth
- SCYX N/A
- FMST N/A
- 52 Week Low
- SCYX $0.66
- FMST $0.55
- 52 Week High
- SCYX $1.66
- FMST $5.74
- Technical
- Relative Strength Index (RSI)
- SCYX 54.46
- FMST 53.04
- Support Level
- SCYX $0.82
- FMST $2.96
- Resistance Level
- SCYX $0.88
- FMST $3.35
- Average True Range (ATR)
- SCYX 0.04
- FMST 0.24
- MACD
- SCYX -0.00
- FMST 0.02
- Stochastic Oscillator
- SCYX 48.45
- FMST 66.48
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.